The possible protective action of sodium-2-mercaptoethanesulfonate (mesna) on hemotoxicity induced by anticancer drugs was tested in normal mice. Mesna (100 mg/kg b.w.) was injected i.v. 1 h before the i.v. administration of cyclophosphamide (10, 120, and 200 mg/kg b.w.), doxorubicin (4.32, 7.2, and 12 mg/kg b.w.) and cis-diamminedichloroplatinum (5.4, 9, and 15 mg/kg b.w.). Results show that in this experimental model mesna does not seem to protect against toxicity of the tested anticancer drug on hemopoietic progenitor cells.
Get full access to this article
View all access options for this article.
References
1.
AllanS.G., SmythJ.F., HayF.G., LeonardR.C.F., WolfC.R.: Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum.Cancer Res., 46: 3569–3573, 1986.
2.
BernackiR.J., BansalS.K., GurtooH.L.: Combination of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors.Cancer Res., 47: 799–802, 1987.
3.
BerriganM.J., MarinelloA.J., PavelicZ., WilliamsC.J., StruckR.F., GurtooH.L.: Protective role of thiols in cyclophosphamide-induced urotoxicity and depression of hepatic drug metabolism.Cancer Res., 42: 3688–3695, 1982.
4.
BlacklockH., BallL., KnightL., ScheyS., PrenticeG.: Experience with mesna in patients receiving allogenic bone marrow transplants for poor prognostic leukemia.Cancer Treat. Rev., 10, Suppl. A: 43–52, 1983.
5.
BlissC.I.: Statistics in Biology.McGraw-Hill, New York, 1970.
6.
BodennerD.L., DedonP.C., KengP.C., KatzJ.C., BorchR.F.: Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.Cancer Res., 46: 2751–2755, 1986.
7.
BradleyR.T., MetcalfD.: The growth of mouse bone marrow cells in vitro.Aust. J. Exp. Biol. Med. Sci., 44: 287–300, 1966.
8.
BrockN., PoheJ.: The development of mesna for regional detoxification.Cancer Treat. Rev., 10, Suppl. A:33–44, 1983.
9.
BrockN., PohlJ., StekarJ., ScheefW.: Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium-2-mercaptoethanesulfonate (mesna).Eur. J. Cancer Clin. Oncol., 18: 1377–1387, 1982.
10.
EvansR.G., WheatleyC., EngelC., NielsenJ., CiborowskiL.J.: Modification of the bone marrow toxicity of cis-diamminedichloroplatinum (II) in mice by diethyldithiocarbamate.Cancer Res., 44: 3686–3690, 1984.
11.
FreireichE.J., GehanE.A., RollD.P., SchmidtL.H., SkipperH.E.: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man.Cancer Chemother. Rep., 3: 13–19, 1972.
12.
GringeriA., BorchR.F.: The effect of diethyldithiocarbamate (DDTC) on bone marrow cells treated with cis-diamminedichloroplatinum (DDP) and its analogs.Proc. Am. Assoc. Cancer Res., 25: 371, 1984.
13.
GurtooH.L., ManelloA.J., BerringanM.J., BansalJ.K., PaulB., PavelicZ.P., StruchR.F.: Effect of thiols on toxicity and carcinostatic activity of cyclophosphamide.Semin. Oncol., 10: 35–45, 1983.
14.
HellmanK., CarterS.K.: Ifosfamide and mesna.Cancer Treat Rev., 10, Suppl. A, 1, 1983.
15.
KleinH.O., KickramanayakeP.D., LoerperC., ChristianE., PohlJ., BrockN.: High-dose ifosfamide and mesna as continuous infusion over five days: a phase I/II trial.Cancer Treat Rev., 10: Suppl. A, 167–173, 1983.
16.
LerzaR., BoglioloG., MuzzuliniC., PannacciulliI.: Failure of N-acetylcysteine to protect against cis-dichlorodiammineplatinum (II)-induced hematopoietic toxicity in mice.Life Sci., 38: 1795–1800, 1986.
17.
MassaG., MazzuliniC., BoglioloG., PannacciulliI.: The effect of N-acetylcysteine on toxicity of cyclophosphamide and doxorubicin on murine hemopoietic progenitors.Life Sci., 36: 1141–1147, 1985.
18.
MillarB.C., MillarJ.L., ClutterbruckR., JinksS.: Studies on the toxicity of cyclophosphamide in combination with mesna in vitro and in vivo.Cancer Treat. Rev., 10, Suppl. A: 63–71, 1983.
19.
NowrousianM.R., SchmidtC.G.: Effects of cisplatin on different haematopoietic progenitor cells in mice.Br. J. Cancer, 46: 397–402, 1982.
20.
OrmstadtK., OhnoY.: N-acetylcysteine and sodium-2-mercaptoethane sulfonate as source of urinary thiol groups in the rat.Cancer Res., 44: 3797–3800, 1984.
21.
OrmstadtK., OrremusS., LastbomT., VeharaN., PohlJ., StekarJ., BrockN.: Pharmacokinetics and metabolism of sodium-2-mercaptoethanesulfonate in the rat.Cancer Res., 43: 333–338, 1983.
22.
PannacciulliI., LerzaR., BoglioloG., MencoboniM., SavianeA.: Effect of diethyldithiocarbamate on hemopoietic toxicity of doxorubicin, cyclophosphamide and cis-diamminedichloroplatinum (II) in an experimental model. Submitted to J. Natl. Cancer Inst.
23.
PannacciulliI., MassaG., BoglioloG., GhioR., SobreroA.: Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells.Cancer Res., 42: 530–534, 1982.
24.
SobreroA., MazzuliniC., D'AmoreF., BoglioloG., MassaG., GhioR., PannacciulliI.: Activity of 4′-epi-doxorubicin on normal hematopoietic precursor cells in mice.Cancer Treat. Rep., 66: 2061–2070, 1982.
25.
TillJ.E., McCullochE.A.: A direct measurement of the radiosensitivity of normal mouse bone marrow cells.Radiat. Res., 14: 213–222, 1961.
26.
WassermanT.H., PhilipsT.L., RossG., KaneL.J.: Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFU, by WR-2721.Cancer Clin. Trials, 4: 3–6, 1981.
27.
YuhasJ.M., CuloF.: Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties.Cancer Treat. Rep., 64: 57–64, 1980.
